In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. e19162-e19162
Abstract:
e19162 Background: Bevacizumab (BEV), an inhibitory monoclonal antibody to VEGF, is widely used to treat patients with non-small cell lung cancer (NSCLC), but biomarkers that predict BEV response are controversial. Reportedly, hypertension is linked to response to BEV therapy, possibly because BEV might suppress vascular nitric oxide (NO) production. However, the usefulness of serum NO (NO s ) as a predictive biomarker for BEV therapy has not previously been shown. Here, we studied the predictive value of NO s in BEV-treated patients with NSCLC. Methods: Fifteen patients with advanced or recurrent NSCLC treated with BEV-based regimens were evaluated retrospectively. Blood samples were taken before treatment (Pre), and after the 1st and 2nd chemotherapy courses (Post 1 and Post 2 , respectively). NO s (NO 2 – /NO 3 – ) was assayed by the Griess method. Relationships between clinical parameters (e.g., clinical responses, adverse events) were analyzed against NO s . This study was approved by the ethics committee of Fukushima Medical University. Results: Mean Pre NO s was 70.3 ±10.5 μmol/L (range: 7.7–138.6 μmol/L). Significant decreases were observed at Post 1 (34.6 ± 6.4 μmol/L; P = 0.013) and Post 2 (29.6 ± 7.6 μmol/L; P = 0.046) compared to Pre values. Post/Pre NO ratios correlated significantly with hypertension onset (Post 1 /Pre: P = 0.012; Post 2 /Pre: P = 0.001). Notably, Post/Pre NO ratios correlated with clinical treatment responses—significantly so for Post 2 /Pre (Post 1 /Pre: P = 0.06; Post 2 /Pre: P = 0.005). Conclusions: NO s , could be a predictive biomarker for response to BEV in patients with NSCLC. Prospective confirmation is needed; we are conducting a prospective translational study of NO in BEV therapy. [Table: see text]
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2013.31.15_suppl.e19162
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2013
detail.hit.zdb_id:
2005181-5
Permalink